Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACET 
Adicet Bio Inc (ACET)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: ACET (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.17
1 Year Target Price $7.17
| 6 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.75% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 99.34M USD | Price to earnings Ratio - | 1Y Target Price 7.17 |
Price to earnings Ratio - | 1Y Target Price 7.17 | ||
Volume (30-day avg) 7 | Beta 1.61 | 52 Weeks Range 0.45 - 1.13 | Updated Date 11/30/2025 |
52 Weeks Range 0.45 - 1.13 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.3 | Actual -0.29 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.13% | Return on Equity (TTM) -71.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11778267 | Price to Sales(TTM) 9.72 |
Enterprise Value 11778267 | Price to Sales(TTM) 9.72 | ||
Enterprise Value to Revenue 2.14 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 153255581 | Shares Floating 134535160 |
Shares Outstanding 153255581 | Shares Floating 134535160 | ||
Percent Insiders 1.46 | Percent Institutions 36.35 |
Upturn AI SWOT
Adicet Bio Inc
Company Overview
History and Background
Adicet Bio, Inc. is a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer. Founded in 2016, the company leverages gamma delta T cell biology to engineer novel cell therapies.
Core Business Areas
- Allogeneic Gamma Delta T Cell Therapies: Development and commercialization of off-the-shelf gamma delta T cell therapies for cancer treatment. This involves engineering gamma delta T cells to enhance their anti-tumor activity.
- CAR-T Cell Therapies: Research and development of CAR-T cell therapies based on gamma delta T cells.
Leadership and Structure
The leadership team includes Chen Schor, President and CEO, and other key executives overseeing research, development, and operations. The organizational structure is typical of a biotechnology company, with distinct departments for research, clinical development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- ADI-001: An allogeneic gamma delta T cell therapy targeting CD20-positive lymphomas. It is currently in clinical trials. Market share is not applicable at this stage as it is not commercially available. Competitors in the lymphoma treatment space include Gilead (Kite Pharma), Novartis, and Bristol Myers Squibb.
- ADI-270: An allogeneic gamma delta CAR-T cell therapy targeting solid tumors. It is currently in clinical trials. Market share is not applicable at this stage as it is not commercially available. Competitors in the solid tumor CAR-T space include companies like BioNTech and several academic institutions.
Market Dynamics
Industry Overview
The cell therapy market is a rapidly growing segment of the biotechnology industry, driven by advances in gene editing and immunotherapy. It is characterized by intense competition and high regulatory hurdles.
Positioning
Adicet Bio is positioned as a specialist in gamma delta T cell therapy, differentiating itself from companies focused on alpha-beta T cell therapies. The company's competitive advantage lies in its expertise in gamma delta T cell biology and its proprietary cell engineering technologies.
Total Addressable Market (TAM)
The total addressable market (TAM) for cell therapies in oncology is estimated to reach $75.5 billion by 2030. Adicet Bio is positioned to capture a portion of this TAM through its gamma delta T cell therapies, specifically by addressing unmet needs in CD20-positive lymphomas and solid tumors.
Upturn SWOT Analysis
Strengths
- Proprietary gamma delta T cell technology platform
- Experienced leadership team
- Promising early-stage clinical data
- Strong intellectual property position
Weaknesses
- Limited clinical data compared to competitors
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Manufacturing complexity
Opportunities
- Expanding pipeline of gamma delta T cell therapies
- Partnerships with larger pharmaceutical companies
- Potential for breakthrough therapy designations
- Addressing unmet needs in solid tumors
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established cell therapy companies
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
Competitive Landscape
Adicet Bio competes with larger, more established pharmaceutical companies in the cell therapy space. Its advantage lies in its focus on gamma delta T cell therapies, which offer potential advantages over traditional alpha-beta T cell therapies.
Growth Trajectory and Initiatives
Historical Growth: Adicet Bio's historical growth has been focused on research and development, with increasing investment in clinical trials.
Future Projections: Analyst projections suggest continued growth in research and development spending, with potential for revenue generation upon successful commercialization of its therapies.
Recent Initiatives: Recent initiatives include advancing ADI-001 and ADI-270 through clinical trials, expanding manufacturing capacity, and exploring potential partnerships.
Summary
Adicet Bio is a biotechnology company specializing in gamma delta T cell therapies, showing promise in early clinical trials. The company faces challenges related to funding, regulatory approvals, and competition from established players. Its proprietary technology and strategic partnerships could drive future growth. However, clinical trial outcomes and manufacturing scalability are critical for its long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (simulated)
- Industry Reports (simulated)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share and financial data are simulated for illustrative purposes.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adicet Bio Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2018-01-26 | CEO, President & Director Mr. Chen Schor BA, CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 152 | Website https://www.adicetbio.com |
Full time employees 152 | Website https://www.adicetbio.com | ||
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.